Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.80 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | BLVRB | P30043 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
| ▸ | PPID | Q08752 | 1/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601 | 1.00 | XDH (0.80) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2635992 | 0.92 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL22745328 | 0.92 | XDH (0.76) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523342 | 0.91 | XDH (0.65) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523355 | 0.90 | XDH (0.68) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL458064 | 0.90 | XDH (0.80) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL22745409 | 0.90 | XDH (0.73) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL29103934 | 0.90 | XDH (0.73) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL29323469 | 0.89 | XDH (0.81) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL30050323 | 0.89 | XDH (0.75) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504640-A | Febuxostat preparation technology | 哈药集团技术中心 | 2025-02-25 | — | — | CN | claimed |
| CN-117924211-A | Preparation method of febuxostat | 哈药集团技术中心 | 2024-04-26 | — | — | CN | claimed |
| CN-115561373-A | Method for detecting febuxostat content and related substances | 河北冀衡药业股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-119841789-A | Preparation method of febuxostat key intermediate | 徐州万邦金桥制药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111072591-B | Febuxostat and intermediates and synthesis thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119504640-A | Febuxostat preparation technology | 哈药集团技术中心 | 2025-02-25 | — | — | CN | disclosed |
| US-12172973-B1 | (E)-2-(3-Cyano-4-isobutoxyphenyl)-N′-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents | King Faisal University (SA) | 2024-12-24 | — | — | US | disclosed |
| CN-118994140-A | Triazole derivative with antidepressant effect, and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994141-A | Phenylthiazole derivative with anti-liver cancer and anti-inflammatory activities and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | disclosed |
| US-12145915-B1 | (E)-2-(3-cyano-4-isobutoxyphenyl)-n′-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents | King Faisal University (SA) | 2024-11-19 | — | — | US | disclosed |
| CN-115724706-B | Method for rapidly converting aldehyde group into cyano group | 中国科学院兰州化学物理研究所 | 2024-04-12 | — | — | CN | disclosed |
| CN-110790720-B | Novel preparation method of febuxostat intermediate | 内蒙古京东药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-109912531-B | Preparation method of high-purity febuxostat | 湖南方盛制药股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115724706-A | Method for quickly converting aldehyde group into cyano group | 中国科学院兰州化学物理研究所 | 2023-03-03 | — | — | CN | disclosed |
| CN-115572272-A | Preparation method of febuxostat and aldehyde ester intermediate thereof | 湖北华世通生物医药科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115561373-A | Method for detecting febuxostat content and related substances | 河北冀衡药业股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145915-B1 | (E)-2-(3-cyano-4-isobutoxyphenyl)-n′-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MT-ND4, NDUFB4 | XDH 918/4885TARBP2 4120/4885ABCC4 7/4885 |
| US-12172973-B1 | (E)-2-(3-Cyano-4-isobutoxyphenyl)-N′-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MT-ND4, NDUFB4 | XDH 918/4885TARBP2 4120/4885ABCC4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.